Adipose-derived stromal cell in regenerative medicine: A review

Table 1 List of clinical trials that use stromal vascular fraction or adipose-derived stromal cells for a variety diseases treatment

Type of cells	Clinical trial phase	Disease	No. of patient	Highlight finding	Ref.
Autologous ADSCs	Phase I	Amyotrophic lateral sclerosis	27 patients	Low back and radicular leg pain were observed, no tumor formation were observed	[35]
Stromal vascular fraction	Phase 0 (CSN111)	Peyronie’s disease	11 patients	No serious adverse events were observed	[36]
Autologous adipose-derived stromal vascular fraction	Phase I	Impaired hand function in patients with systemic sclerosis	12 patients	Four minor adverse events were observed, hand disability and pain were decreased	[54]
Autologous adipose-derived stromal vascular fraction	Phase I (NTC01813279)	Impaired hand function in patients with systemic sclerosis	12 patients	Mobility, strength and fibrosis of the hand was improved	[55]
Autologous adipose-derived stromal vascular fraction	Phase 0	Systemic sclerosis	12 patients	Finger oedema, skin sclerosis, motion and strength of the hands were ameliorated, hand pain was decreased	[49]
Stromal vascular fraction combined with PRP	Phase 0 (NCT02097862)	Degenerative disc disease	15 patients	No serious adverse events were observed	[37]
Autologous ADSCs	Phase I/II	Osteoarthritis	18 patients	Adverse events were observed in several patients, including urinary stone, arthralgia, pain and tenderness in the pes anserinus of the ipsilateral knee; ADSCs injection into the osteoarthritic knee ameliorated function and pain of the knee joint	[45]
ADSC	Phase 0 (NCT02357485)	Osteoarthritis	6 patients	No serious adverse events were observed, pain for osteoarthritis of the knee was decreased	[38]
Stromal vascular fraction containing ADSCs	Phase 0	Osteochondral lesions of the talus	49 patients	SVF Containing ADSCs administration was a therapeutically beneficial strategy for osteochondral lesions of the talus	[50]
Expanded ADSCs	Phase 0	Patients with a desire to become pregnant (with Crohn's Perianal Fistula)	6 patients	Local administration of ADSCs did not impact on course of pregnancy or newborn development;	[39]
Adipose-derived mesenchymal stem cell	Phase I/II (NCT02513238)	Salivary gland hypofunction and radiation-induced xerostomia	30 patients	No serious adverse events were observed Change in unstimulated whole salivary flow rate was observed; no serious adverse events were observed	[40]
ADSC	Phase 0	Alopecia	20 patients	Hair diameter and density were improved,the efficacy and the safety of the treatment with ADSCs was confirmed	[51]
Conditioned media of adipose tissue-derived stem cells	Phase 0	Female pattern hair loss	27 patients	Hair density was enhanced, hair thickness was improved	[52]
ADSC conditioned medium	Phase 0	Alopecia	22 patients	Hair numbers were considerably enhanced	[53]
Expanded autologous ADSC	Phase 0	Type 2 diabetes mellitus	3 patients	Blood glucose levels were decreased in all patients, no serious adverse events were observed	[41]

ADSCs: Adipose-derived stromal cells; PRP: Platelet-rich plasma.